Amicus Therapeutics Inc. (FOLD) provided updates and detailed the statistical analysis plan for its second Phase 3 study of the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients with amenable mutations Monday morning.
Amicus Therapeutics has spiked sharply to the upside in the last 15 minutes on increased volume and is currently higher by 0.75 at $3.78. The stock has soared to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.